#United States #Jersey City #WallachBeth Capital #Tawon Medical #Sacro-Pelvic Disorders

WallachBeth Capital Completes Private Placement for Tenon Medical

On August 31, 2026, WallachBeth Capital LLC, a prominent figure in capital markets and institutional execution services, announced the successful closure of a private placement offering for Tenon Medical, Inc. This innovative medical device company is dedicated to transforming healthcare solutions for patients suffering from specialized sacro-pelvic disorders.

The offering consisted of 597,610 shares of common stock, alternatively offering pre-funded warrants, coupled with an associated warrant allowing for the purchase of up to 1,058,517 additional shares of the company’s common stock. Both these financial instruments were part of an investment strategy to generate $3 million in gross proceeds for Tenon Medical.

The effective offering price for each share of common stock along with the accompanying warrants stands at $5.02, while the pre-funded warrants are priced at $5.019 with a nominal exercise cost of $0.001 per share. The investor has also been granted customary registration rights, ensuring compliance with state and federal securities regulations.

This strategic financing initiative not only strengthens Tenon's financial footing but also positions them to focus on the development of their specialized medical technologies. As healthcare providers and institutions are continuously looking for effective solutions in pain management and treatment, Tenon’s innovative approach provides them with promising options.

WallachBeth Capital played the pivotal role of exclusive placement agent during this transaction, leveraging its vast experience in structuring private placements and guiding them through the complexities of capital raises. Their involvement underscores their commitment to supporting emerging companies in the healthcare sector.

According to industry experts, the market for medical devices targeting sacro-pelvic disorders is experiencing significant growth, propelled by an increasing prevalence of related conditions and an aging population. As a result, Tenon Medical is positioned to capitalize on this market dynamic with its pioneering solutions.

The closure of this funding round follows earlier announcements regarding the pricing of the offering, emphasizing WallachBeth’s strategic guidance throughout the process. Furthermore, this transaction is governed by the Securities Act, ensuring that all applicable regulations are adhered to, thereby safeguarding both the company and its investors.

In a larger context, WallachBeth Capital’s focus on medical technology financing is indicative of a broader market trend, where healthcare innovations are attracting substantial investments. Investors are increasingly recognizing the potential for growth in segments that cater to specific medical challenges.

With this successful funding round, Tenon Medical is expected to further enhance its research and development initiatives, pushing towards advancements that promise to improve patient outcomes significantly. The release of this news marks a pivotal moment for both WallachBeth and Tenon as they seek to drive change within the medical landscape, innovating for the future of healthcare.

As we look forward, the collaboration between WallachBeth Capital and Tenon Medical is expected to deepen, potentially leading to further strategic initiatives that could reshape the treatment landscape for sacro-pelvic disorders and beyond.